Journal of psychopharmacology (Oxford, England)
June 5, 2025
Ben Beaglehole, Paul Glue, Shona Neehoff et al.
19 citations
We previously completed a double-blind randomised crossover study assessing intramuscular ketamine for treatment-resistant depression (TR-D), post-traumatic stress disorder (TR-PTSD) and obsessive-compulsive disorder (TR-OCD). Here, we report an extension study to explore the ongoing benefits and tolerability of maintenance oral ketamine. All participants from the original study were eligible...
Cells
June 3, 2025
Marta Jóźwiak-Bębenista, Anna Wiktorowska-Owczarek, Małgorzata Siatkowska et al.
4 citations
Despite affecting millions worldwide, major depressive disorder (MDD) remains a therapeutic challenge, with approximately one-third of patients failing to respond to standard treatments. The need for innovative, molecularly driven therapies has turned attention to ketamine and its enantiomers. While S-ketamine is clinically approved for treatment-resistant depression (TRD), it has various...
Pharmacopsychiatry
June 2, 2025
Ludovic C Dormegny-Jeanjean, Suzie Lenoir, Ilia Humbert et al.
1 citation
Ketamine and esketamine (ESK) offer new treatment options for resistant depression. Unlike traditional antidepressants, they can be used in combination with non-selective monoamine oxidase inhibitors (NS-MAOI) without the risk of serotonergic syndrome. However, potential sympathomimetic synergy may lead to elevated blood pressure (BP). This series investigates whether cardiovascular parameters...
The Brown University Psychopharmacology Update
June 1, 2025
Results of a systematic review and meta‐analysis suggest that esketamine has only modest efficacy in the treatment of adults with treatment‐resistant depression, with initial improvement diminishing after the first few days. The results also suggest no effect of esketamine on suicidality.
BJPsych Open
June 1, 2025
Anna Borissova, Allan H. Young, Mitul A. Mehta et al.
Aims: Ketamine and behavioural activation (BA) reduce levels of anhedonia in major depressive disorder (MDD), though neither resolves anhedonia. Combining these treatments could yield additive or even multiplicative benefits. This poster summarises the development of a PhD fellowship proposal, discussing: (1) the initial patient and public involvement (PPI) interviews, exploring views on...
BJPsych Open
June 1, 2025
Ranjini Rao
Aims: 1. Examine efficacy and durability of antidepressant effects. 2. Identify specific symptoms of improvement. 3. Compare response rates and duration of antidepressant effects in failed to respond to previous treatments. Methods: Prospective review study of patients who received off-label rapid dissolve wafer for SL delivery in hospital setting 2–3 times a week for 4 weeks. The study...
BJPsych Open
June 1, 2025
Minna Chang, Allan H. Young, Mario F Juruena
Aims: Ketamine is a novel and exciting putative antidepressant medication for patients with treatment-resistant depression. A complication commonly seen in frequent and heavy recreational use of ketamine is ulcerative cystitis, which presents with lower urinary tract symptoms (LUTS) and upper renal tract damage and can be seen in over 25% of regular users. Although ketamine-induced cystitis...
CHEST critical care
June 1, 2025
Lucas C Wollenman, Austin M Tipold, Matthew W. Semler et al.
1 citation
One of 3 patients in the ICU receiving mechanical ventilation demonstrates posttraumatic stress disorder (PTSD). A single dose of ketamine has been shown to reduce PTSD symptoms in outpatients with chronic PTSD, but its long-term effect is unknown in patients who are critically ill and mechanically ventilated. Is ketamine, when used for induction of anesthesia before emergency tracheal...
Biuletyn Głównej Biblioteki Lekarskiej
June 1, 2025
Christian S. Skowron, Urszula Miłkowska, Gabriela Maria Piech et al.
Abstract Major depressive disorder (MDD), including treatment-resistant depression (TRD), represents significant global health challenges with conventional therapies often yielding suboptimal outcomes. This narrative review examines the therapeutic potential of psilocybin and ketamine, two novel agents offering distinct mechanisms of action compared to traditional monoamine-based or monoamine...
Cureus
June 1, 2025
Amy Avakian, Zachary I Merhavy
1 citation
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, synaptic dysfunction, and neuroinflammation. Despite extensive research, current therapeutic options offer limited symptomatic relief without altering disease progression. Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist traditionally used as an anesthetic, has garnered...